Chemours (CC) PT Raised to $19 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq edge higher ahead of midterm results; Apple falls
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts CC Hot Sheet
Price: $13.38 +1.67%
Rating Summary:
7 Buy, 11 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 16 | New: 12
Rating Summary:
7 Buy, 11 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 16 | New: 12
Join SI Premium – FREE
RBC Capital analyst Arun Viswanathan raised the price target on Chemours (NYSE: CC) to $19.00 (from $15.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Chemours (CC) Misses Q3 EPS by 6c, Misses on Revenue; Offers Guidance
- Vertex (VRTX) PT Raised to $563 at Stifel
- Apple (AAPL) PT Raised to $295 at DA Davidson Despite Disappointing Services Growth
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
